Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A chromosome-level genome assembly of Neotoxoptera formosana (Takahashi, 1921) (Hemiptera: Aphididae).

G3 (Bethesda, Md.)·2022

Same author

Genetic encoding of an esophageal motor circuit.

Cell reports·2022

Same author

Stress Monitoring of Concrete via Uniaxial Piezoelectric Sensor.

Sensors (Basel, Switzerland)·2022

Same author

Resolving mutational signatures in cancer development.

Cancer cell·2022

Same author

Catalytic mechanisms underlying fungal fatty acid desaturases activities.

Critical reviews in biotechnology·2022

Same author

Recent developments in horizontal gene transfer with the adaptive innovation of fermented foods.

Critical reviews in food science and nutrition·2022

Search research articles

Related Experiment Video

Updated: May 20, 2025

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

Multi-Pathway Study for Oxaliplatin Resistance Reduction.

Tong Ye¹, Chen Wu², Jintong Na³

¹State Key Laboratory of Targeting Oncology, National Center for International Research of Bio-Targeting Theranostics, Guangxi Key Laboratory of Bio-Targeting Theranostics, Guangxi Medical University, Nanning 530021, China.

Current Issues in Molecular Biology

|March 26, 2025

Summary

This summary is machine-generated.

This study explores overcoming oxaliplatin resistance in cancer treatment. A new CDC7 inhibitor, XL413, shows promise in enhancing chemotherapy effectiveness and reducing side effects.

Keywords:

anticancer mechanism cancer therapy combination therapy drug resistance oxaliplatin

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Experiment Videos

Last Updated: May 20, 2025

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Area of Science:

Oncology
Pharmacology
Cancer Biology

Background:

Platinum-based chemotherapy, including oxaliplatin, faces limitations due to toxicity and drug resistance.
Oxaliplatin is a crucial first-line antitumor agent requiring optimized administration to balance efficacy and side effects.

Purpose of the Study:

To review current developments in cancer therapy, focusing on oxaliplatin's mechanisms, resistance, and amelioration strategies.
To investigate the potential of XL413, a novel CDC7 inhibitor, in overcoming oxaliplatin resistance and enhancing treatment outcomes.

Main Methods:

Literature search of PubMed and X-MOL databases using keywords: Oxaliplatin, XL413, drug resistance, cancer treatment.
Boolean logic applied to refine search strategy for relevant biological publications.
Analysis of 140 selected publications on oxaliplatin's anticancer effects, resistance mechanisms, and the role of XL413.

Main Results:

Identified mechanisms of oxaliplatin's anticancer effects and challenges in clinical application.
Characterized various pathways of oxaliplatin resistance and strategies for its mitigation.
Highlighted XL413 as a promising agent for improving oxaliplatin-based cancer therapy.

Conclusions:

Oxaliplatin resistance is a significant challenge in cancer treatment, necessitating novel therapeutic approaches.
XL413 presents a potential strategy to enhance the efficacy of oxaliplatin chemotherapy.
Further research into CDC7 inhibition may lead to improved cancer treatment regimens.